Cycle Pharmaceuticals Selects LeMed as Exclusive U.S. Distribution & Services Partner for HARLIKU

Cycle Pharmaceuticals has awarded LeMed Specialty Pharmacy the exclusive contract for specialty pharmacy distribution and services for HARLIKU (nitisinone) Tablets, the first and only FDA-approved treatment for use in alkaptonuria (AKU).

LeMed will manage commercial and non-commercial dispensing for HARLIKU across the United States.

“We’re excited to extend our partnership with LeMed Specialty Pharmacy, building on years of successful collaboration across rare diseases. Together, we remain dedicated to putting patients first— ensuring those living with AKU receive the support and treatment they need, now and into the future,” said Chikai Lai, SVP & CCO, Cycle Pharmaceuticals

“We are honored Cycle chose LeMed to ensure every eligible AKU patient gets timely access to HARLIKU,” said Nathaniel Keifer, Vice President, Client Strategy at LeMed Specialty Pharmacy. “Our one-size-fits-one bespoke model pairs clinical excellence and a patient-experience mindset with real-time data insights and an agile infrastructure, enabling Cycle to monitor outcomes and scale when necessary while patients experience the speed to therapy and support they deserve.”